glp 1 agents How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments Holding GLP-1 Agonists Prior to

Next steps The researchers noted that there is much more work to do around this topic

Although robust evidence is lacking for the primary prevention of cardiovascular disease using a combination of SGLT2is and GLP1-RAs, meta-analyses suggest potential benefits

The harder population to reach is the one without a diabetes diagnosis, members who are overweight or have obesity and carry cardiovascular risk, perhaps taking a statin or a blood pressure medication, but whose A1C hasn't yet crossed the threshold for a diabetes diagnosis

Understanding these molecular targets provides clinicians with insight into BPC-157's broad therapeutic potential across tissue types